Atezolizumab Monotherapy Improves Survival in Frontline PD-L1-High NSCLC
Single-agent atezolizumab extended overall survival compared with chemotherapy as a frontline treatment for patients with advanced nonsquamous and squamous non–small cell lung cancer and high PD-L1 expression, according to topline findings from the phase III IMpower110 trial.
Source: OncLive